Related Experiment Video
Updated: Dec 23, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival
Stuart J McCarter1, Elizabeth A Coon1, Rodolfo Savica1
1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Background:
Multiple system atrophy (MSA) is a neurodegenerative disorder from α-synuclein aggregation. in vitro studies suggest vitamin B12 may interrupt α-synuclein-mediated neurodegeneration. The objective of this study was to determine whether serum vitamin B12 level at MSA diagnosis is associated with survival.
Methods:
One hundred eighty-two MSA patients evaluated at Mayo Clinic with vitamin B12 testing were studied. We determined the risk of death in relationship to serum vitamin B12 levels at MSA diagnosis, adjusting for predictors of poor survival.
Results:
Predictors of shorter survival included vitamin B12 < 367 ng/L (HR, 1.8; 95% CI, 1.3-2.7), falls within 3 years of MSA diagnosis (HR, 1.6; 95% CI, 1.1-2.3), bladder symptoms (HR, 1.6; 95% CI, 1.0-2.6), urinary catheter requirement (HR, 1.7; 95% CI, 1.0-2.8), male sex (HR, 1.4; 95% CI, 1.0-2.0), and MSA-P subtype (HR, 1.5; 95% CI, 1.0-2.0).
Conclusions:
Low vitamin B12 levels are associated with shorter survival in MSA. Additional studies to explore this observation and assess the potential role of vitamin B12 as a modifiable survival factor are needed. © 2020 International Parkinson and Movement Disorder Society.
Insights
Low vitamin B12 levels are linked to shorter survival in patients with Multiple System Atrophy (MSA). This finding suggests vitamin B12 may be a modifiable factor influencing MSA prognosis.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by alpha-synuclein aggregation.
- In vitro research indicates that vitamin B12 might play a role in mitigating neurodegeneration caused by alpha-synuclein.
Purpose of the Study:
- To investigate the association between serum vitamin B12 levels at the time of MSA diagnosis and patient survival.
- To identify if vitamin B12 status is a prognostic indicator in MSA.
Main Methods:
- A cohort of 182 patients diagnosed with MSA at Mayo Clinic were analyzed.
- Serum vitamin B12 levels were measured at diagnosis, and survival data were collected.
- Statistical analysis adjusted for known predictors of survival to determine the risk of death associated with vitamin B12 levels.
Main Results:
- Lower serum vitamin B12 levels (<367 ng/L) at MSA diagnosis were significantly associated with shorter survival (Hazard Ratio [HR], 1.8; 95% Confidence Interval [CI], 1.3-2.7).
- Other predictors of shorter survival included falls, bladder symptoms, urinary catheter requirement, male sex, and the MSA-P subtype.
Conclusions:
- Serum vitamin B12 levels at diagnosis are associated with survival outcomes in patients with Multiple System Atrophy.
- Further research is warranted to explore this relationship and evaluate vitamin B12 as a potential modifiable factor to improve MSA survival.
More Related Videos
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
Vitamins
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test